Endocrine therapy showed a trend toward reduced contralateral breast events (HR 0.61; 95% CI, 0.31–1.20), while chemotherapy was associated with lower distant recurrence risk (HR 0.48; 95% CI, 0.22–0.96).
← all excerpts
Breast-Conserving Surgery in <i>BRCA</i> Mutation Carriers: A Paradigm Shift Toward Individualized, Multidisciplinary Care.
1
—
—